28
Could
2024
This June world-leading most cancers researchers from across the globe are on the brink of current and talk about the most recent advances within the oncology on the 2024 ASCO Annual assembly in Chicago. Forward of the assembly, we have a look at a few of the ICR’s analysis being offered this yr.
Posted on 28 Could, 2024
by Laura Milne
From 31 Could – 4 June, scientists from The Institute of Most cancers Analysis, London, will be a part of a world discussion board of world-leading researchers and oncologists on the 2024 American Society of Scientific Oncology (ASCO) Annual Assembly.
The ASCO convention sees the most recent, practice-changing outcomes from main section III trials offered alongside thrilling early section trial outcomes, translational analysis, and insightful commentary on all features of oncology. The convention is the spotlight of the worldwide most cancers analysis calendar.
The theme of this yr’s assembly is The Artwork and Science of Most cancers Care: From Consolation to Treatment which focuses on showcasing state-of-the-art analysis, ground-breaking therapies, and visionary insights that can rekindle attendees ardour for oncology.
Under is a abstract of research being offered by researchers from the ICR and our companions The Royal Marsden NHS Basis Belief at ASCO 2024.
To entry the complete programme with particular timings and places go to the ASCO web site.
Displays
Friday 31 Could
Oral shows
Capivaseratib With Fulvestrant for Breast CancerNicholas Turner
Schooling session1pm
Saturday 1 June
Oral shows
The Energy of Two: Focused Remedy Mixtures
Susana N. BanerjeeDiscussion1.51pm
Impact of polygenic threat rating for clinically vital prostate most cancers in a screening program: The BARCODE 1 research outcomes.
Ros A. EelesAbstract: 105003pm
Baseline ctDNA analyses and associations with outcomes in taxane-naive sufferers with mCRPC handled with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
Johann S. De BonoAbstract: 50085.24pm
Poster shows
Sunday 2 June
Oral shows
Extremely-sensitive ctDNA mutation monitoring to establish molecular residual illness and predict relapse in sufferers with early breast most cancers.
Isaac Garcia-MurillasClinical Science Symposium.Summary: 10104:42pm
Discriminating subtypes in superior breast most cancers with ctDNA methylation profiling.
Nida PashaClinical Science Symposium.Summary: 10135:18pm
Poster shows
H3B-6545 + palbociclib in sufferers (pts) with domestically superior/metastatic oestrogen receptor constructive (ER+), HER2 unfavourable (–) breast most cancers (BC).
Stephen JohnstonAbstract 1051: poster board 299.00am
Tucatinib and trastuzumab for beforehand handled HER2−mutated metastatic breast most cancers (SGNTUC−019): A section 2 basket research.
Alicia OkinesAbstract 1105: poster board 839.00am
METRADS-P vs. RECIST/PCWG standards to detect illness development in metastatic castration-resistant prostate most cancers (mCRPC).
Nina TunariuAbstract 5070: poster board 4769.00am
Monday 3 June
Oral presentation
BEAT-meso: A randomized section III research of bevacizumab (B) and commonplace chemotherapy (C) with or with out atezolizumab (A), as first-line therapy (TX) for superior pleural mesothelioma (PM)—Outcomes from the ETOP 13-18 trial.Sanjay PopatAbstract: LBA8002:8.12am
Tuesday 4 June
Oral presentation
Concentrating on of DNA-Harm Signaling ProteinsAndrew TuttEducation Session9:45am
Be part of the dialog on social media with the hashtag #ASCO24.
Learn extra information and tales from the ASCO Annual Assembly:
ASCO Annual Assembly
feedback powered by